RarePlex® CTC Assays

RarePlex AR/ARv7 CTC Panel Kit
Prostate Cancer Markers

Panel Kit for Prostate Cancer Markers

Prostate cancer is the second most common type of malignancy and one of the leading causes of cancer deaths in men worldwide. Since androgen-mediated signaling is the predominant driver of prostate cancer proliferation, the androgen receptor (AR) is an important therapeutic target.

Therapeutics have been developed that target the ligand-binding domain of the AR protein. It has been determined that some patients may not benefit from these treatments or may develop secondary resistance since they do not express this ligand-binding domain.

Detection in patients' circulating tumor cells (CTCs) of androgen receptor splice variant 7 (ARv7), lacking the ligand-binding domain, shows a link with treatment failure. Identification of ARv7 in CTCs could help determine if a patient has become resistant to AR-targeted therapies.

The RarePlex AR/ARv7 CTC Panel Kit (assay code 0904-LB) provides highly accurate, repeatable, and precise results for CTC count and AR and ARv7 biomarker expression, and is suitable for use in large, multi-center clinical trials of prostate cancer.

Talk to an expert

Benefits of the AR/ARv7 CTC Assay

  • Simple processing of blood to slides for sample banking
  • Convenient pause points in the workflow enable sample control and transport from remote collection sites
  • Flexible sample handling — processing and analysis may be performed at the same site or at a separate clinical research laboratory
  • Extensive validation and a highly automated workflow yield accurate and highly reproducible results
  • Worldwide network of CROs equipped to run the workflow in support of global clinical trials

Clinical & Validation Data

22Rv1 cell line stained with AR/ARv7 Panel Kit

22Rv1 cell line stained with 0904-LB AR/ARv7 CTC Panel Kit. Scale bar represents 10μm.

AR and ARv7 MFI validation data

A: Per-cell ARv7 MFI for 22Rv1 and BT-474 spike-in slides. Optimum threshold for positivity is 80 for ARv7 (dashed copper line).

B: Per-cell AR MFI for 22Rv1 and PC3 spike-in slides. Optimum threshold for positivity is 120 for AR.

Assay Design & Validation

RarePlex® CTC Assays: Design and Analytical Validation for Circulating Tumor Cells. Presented by Dr. Tad George, Sr. VP of Biology R&D.

Gain insight into the principles RareCyte applies to its assay design and validation process in this 11 minute video.

Read transcript →

Additional Resources

Download the specification sheet Download Test Menu catalog Contact us to learn more

References

  1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates. CA Cancer J Clin. 2018;68(6):394-424.
  2. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89.
  3. Cioni B, et al. Loss of androgen receptor signaling in prostate cancer-associated fibroblasts promotes CCL2- and CXCL8-mediated cancer cell migration. Mol Oncol. 2018;12(8):1308-1323.
  4. Helsen C, et al. Androgen receptor antagonists for prostate cancer therapy. Endocrine-Related Cancer. 2014;21(4):T105–18.

Get started with your CTC program


Contact a specialist